熱門資訊> 正文
Gossamer Bio宣布进行高达2.5亿美元的私募
2026-08-21 21:19
- Gossamer Bio (GOSS) announced on Friday a private placement expected to provide up to approximately $250M in gross proceeds.
- The financing includes $150M of committed capital, with approximately $25M funded at the initial closing and another $125M upon FDA acceptance of the seralutinib NDA in pulmonary arterial hypertension, or PAН.
- The offering is expected to close on or about August 24, 2026.
- FDA approval warrants could provide up to an additional $100M in gross proceeds at an exercise price of $0.187 per share.
- The financing includes participation from new and existing institutional investors, including EcoR1 Capital, 683 Capital Partners, RA Capital Management, Coastlands Capital, Samsara BioCapital, and Rock Springs Capital.
- Proceeds will support seralutinib through potential FDA approval in PAH.
More on Gossamer Bio
- Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates Transcript
- Seeking Alpha’s Quant Rating on Gossamer Bio
- Historical earnings data for Gossamer Bio
- Financial information for Gossamer Bio
推薦文章
一圖看懂 | 華夏富時港股高息ETF開啟申購！入場門檻為1000港元
美股前瞻 | 聯儲局再傳「鷹聲」！美債收益率應聲走高，納指期貨跌近1%；中美第八輪經貿磋商達成多項共識；Meta全面押注個人Agent
一周財經日曆 | 影響加息大事！9月大小非農數據重磅登場；美光、希音齊放榜！景旺電子、歡創科技等5只新股下周上市
Q4淨利或狂飆逾1000%！美光能否交出」炸裂「財報？三大焦點將影響股價走向
休市提醒：中秋假期來臨，港股9月25日（周五）正常開市
華盛早報 | 強勁PMI催高加息預期！納指回調1%；美財政部擬再回購60億美元長債；SpaceX總裁套現逾5200萬美元
美股前瞻 | 特朗普最新調倉曝光！拋售微軟，買入英偉達；Meta科技盛會重磅來襲；高盛、德銀齊看多：標普500將衝刺8000點
特朗普將亮相聯大：聚焦伊朗 密集會見多國領導人 計劃與丹麥簽署協議
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
